Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 11/20 | 0.59 |
| ▸ | ADORA2B | P29275 | 11/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 10/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.36 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.36 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6134083 | 0.85 | ADORA2A (0.65) | ADORA2AADORA2BADORA1ADORA3CYP1A2 | |
| SCHEMBL6134324 | 0.82 | ADORA1 (0.47) | ADORA2AADORA2BADORA1 | |
| SCHEMBL6134198 | 0.81 | FGFR1 (0.39) | ADORA2AADORA2BADORA1 | |
| SCHEMBL6134903 | 0.80 | ADORA1 (0.39) | ADORA2AADORA2BADORA1 | |
| SCHEMBL6134252 | 0.80 | ADORA2A (0.38) | ADORA2AADORA2BADORA1 | |
| SCHEMBL6133826 | 0.79 | CLK1 (0.36) | ADORA2AADORA2BADORA1 | |
| SCHEMBL6134855 | 0.79 | KDM5B (0.36) | ADORA2AADORA2BADORA1 | |
| SCHEMBL6134468 | 0.79 | ADORA2A (0.37) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL21176829 | 0.79 | ADORA2A (0.76) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL6134078 | 0.79 | GFER (0.41) | ADORA2AADORA1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ASTELLAS PHARMA INC. (JP) | 2005-02-24 | — | — | US | disclosed |
| WO-2003057689-A1 | AMINOPYRIMIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ADORA2B, ADORA2A, ADORA1 | ADORA2A 2/4885ADORA2B 1/4885ADORA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.